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Abstract
Aims/hypothesis Insulin-like growth factor-1 is a major
childhood growth factor and promotes pancreatic islet cell
survival and growth in vitro. We hypothesised that genetic
variation in IGF1 might be associated with childhood
growth, glucose metabolism and type 1 diabetes risk. We
therefore examined the association between common
genetic variation in IGF1 and predisposition to type 1
diabetes, childhood growth and metabolism.
Materials and methods Variants in IGF1 were identified by
direct resequencing of the exons, exon–intron boundaries
and 5′ and 3′ regions in 32 unrelated type 1 diabetes patients.
A tagging subset of these variants was genotyped in a
collection of type 1 diabetes families (3,121 parent–child
trios). We also genotyped a previously reported CA repeat in
the region 5′ to IGF1. A subset of seven tag single nucleotide
polymorphism (SNPs) that captured variants with minor
allele frequency (MAF) ≥0.05 was genotyped in 902
children from the Avon Longitudinal Study of Parents And
Children with data on growth, IGF-1 concentrations, insulin
secretion and insulin action.
Results Resequencing detected 27 SNPs in IGF1, of which 11
had a MAF>0.05 and were novel. Variants with MAF≥0.10
were captured by a set of four tag-SNPs. These SNPs showed
no association with type 1 diabetes. In children, global
variation in IGF1 was weakly associated with IGF-1 concen-
trations, but not with other phenotypes. The CA repeat in the
region 5′ to IGF1 showed no association with any phenotype.
Conclusions/interpretation Common genetic variation in
IGF1 alters IGF-1 concentrations but is not associated with
growth, glucose metabolism or type 1 diabetes.
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Introduction
Type 1 diabetes is a common autoimmune disorder that arises
by an interaction between genes and the environment. To date,
ten loci have been identified including the HLA class II genes,
the cytotoxic T-lymphocyte associated protein 4 (CTLA4)
locus, protein tyrosine phosphatase, non-receptor type 22
(lymphoid) (PTPN22), IL-2 receptor, alpha (IL2RA), inter-
feron induced with helicase C domain 1 (IFIH1) and four
novel loci identified by a genome-wide association study [1].
The protein products of these genes play important roles in
antigen presentation and the cellular immune response,
highlighting the importance of the immune system in the
pathogenesis of type 1 diabetes. However, not all patients with
evidence of islet autoimmunity develop complete beta cell
failure [2]. Given the evidence to suggest that early weight
gain and growth in childhood are associated with type 1
diabetes [3], it is possible that factors influencing insulin
action (body weight and fat mass) and islet function may
predispose to or influence the presentation of type 1 diabetes.
Lower IGF-1 concentrations predict the development of
glucose intolerance in adults [4]. George et al. reported that
islet overexpression of IGF1 in diabetic mice enabled islet
regeneration and gradual correction of hyperglycaemia and
hypoinsulinaemia [5]. A microsatellite in the region 5′ to
IGF1 has been associated with adult height, cardiovascular
risk, osteoporosis and type 2 diabetes in some [6] but not all
[7] studies.
Since common variation in IGF1 could alter circulating
IGF-1 concentrations and therefore body habitus, insulin
action and beta cell secretion, we sought to determine the
associations, if any, between IGF1 and circulating IGF-1
concentrations, size at birth, both fasting and postprandial
insulin concentrations, and type 1 diabetes.
Materials and methods
Polymorphism identification
DNA samples from 32 randomly selected type 1 diabetic
probands were amplified using specifically designed forward
and reverse primers. This provided 88% probability of detecting
single nucleotide polymorphisms (SNPs) with minor allele
frequencies (MAF) of 0.033, 96% probability for MAF 0.05
and 99.8% for MAF 0.10 [8]. Resequencing included the 3 kb
region 5′ to the gene, all exons and exon–intron boundaries
and 3′ untranslated region. Four 1 kb segments in the second
intron, ~10 kb intervals apart, were also resequenced.
Tag-SNP selection
The resequencing genotype data were used to select SNP
subsets that predicted the genotypes of the remainder, using a
coefficient of determination, R2, which measures the ability
to predict each known SNP genotype by linear regression on
the tag-SNP genotypes [9]. We considered only SNPs with a
MAF≥0.10 in the type 1 diabetes collection and ≥0.05 in the
Avon Longitudinal Study of Parents And Children
(ALSPAC) cohort (for details see below and Electronic
supplementary material [ESM]), using a minimum R2 of 0.8.
Genotyping
All genotyping data were double-scored to minimise error. All
genotypes were in Hardy–Weinberg equilibrium (p>0.05).
Populations studied
All DNA samples were collected after ethics approval and
informed consent had been obtained.
Type 1 diabetes family collection Type 1 diabetes families
were of white European descent, with two parents and at
least one affected child. The populations studied have been
described previously [8].
ALSPAC Details of this birth cohort are available on the
ALSPAC website (www.alspac.bris.ac.uk). The children in
this study are from a 10% ‘Children in Focus’ sub-cohort
(1,335 full-term singleton infants) randomly selected from the
last 6 months of recruitment for more detailed measurements
of growth. Birthweight was noted from hospital records, and
length and head circumference were measured after birth. At
age 7 years (mean age 7.5±0.1 years), body weight and
height were measured. Body composition was assessed at age
9 years by whole-body dual-energy X-ray absorptiometry.
Internal SD scores were calculated for all parameters of
growth to adjust for age and sex. IGF-1 concentrations were
measured in cord blood samples (birth) and in venous blood
(7 or 8 years of age). Fasting insulin sensitivity was assessed
by the homeostatic model assessment index (www.dtu.ox.ac.
uk/homa/) and insulin secretion at 30 min post oral glucose
by the insulinogenic index at age 8 years.
Statistical analysis
All statistical analyses to test the association between IGF1
and type 1 diabetes were performed in either Stata (www.
stata.com/) or R (www.r-project.org/) statistical systems.
Additional routines may be downloaded (www-gene.cimr.
cam.ac.uk/clayton/software/). Missing tag-SNP genotypes
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were imputed under the null hypothesis and were analysed
using a multilocus test [9]. The microsatellite, 5′ IGF1 CA
repeat, was analysed using TRANSMIT [10]. The global
effect of the IGF1 tag-SNP set on each outcome variable was
entered into a multi-locus regression model. R2 change was
taken as the contribution to the total variation in each
outcome. Associations of IGF1 SNPs with growth and
metabolic phenotypes were analysed using univariate
ANOVA (general linear models). The association of the 5′
IGF1 CA repeat was analysed by comparing the wild-type
allele (192 bp) to all other alleles [6, 7].
For further details on Materials and methods section, see
ESM.
Results
Genetic variation in IGF1
Resequencing identified 27 novel polymorphisms consist-
ing of 24 SNPs, one rare non-synonymous SNP in exon 3
(Ala to Thr) and two deletion/insertion polymorphisms.
Eleven SNPs had a MAF>0.05. Four tag-SNPs (Table 1)
were selected and genotyped in the type 1 diabetes families
studied. In ALSPAC, seven tag-SNPs were selected (ESM
Table 1).
IGF1 and type 1 diabetes
The selected tag-SNPs were genotyped in 2,439 families
(3,121 parent–child trios). The multilocus test of the IGF1
tag-SNPs provided no evidence of an association with type
1 diabetes (χ4
2=4.4; p=0.356; Table 1). The microsatellite,
5′ IGF1 CA repeat, was genotyped in 2,109 families and
analysed using TRANSMIT [10]. There was no evidence of
association (p=0.358) (ESM Table 2).
Wellcome Trust Case Control Consortium data
We used data from the Wellcome Trust Case Control
Consortium (WTCCC) genome-wide association study [1]
to test association of the extended IGF1 region with type 1
diabetes. The region contained 22 SNPs. When the
WTCCC data were analysed using a logistic regression
model adjusted for variation in allele frequencies across
Great Britain, no evidence of association of these SNPs
within the region was found (ESM Table 3).
Association with IGF-1 concentrations
In the ALSPAC children, multilocus regression models
showed that the IGF1 tag-SNP set was associated with IGF-
1 protein levels at birth (R2=0.063; p=0.029) and weakly
Table 1 A summary of IGF1 tag-SNPs genotyped in 2,396 families
Parameter Tag-SNP
rs35140968a rs6214 rs3730220 s6219
Sequence AAATAACT[-/AT]
CTCAAATA
GACTTAAC[A/G]
TGTTTTCT
CAGGTTGG[A/T]
CTCAAACT
AACCTCAA[A/G]
CTGTCTAC
Allele coding,
1 (minor)/2
Ins/Del A/G T/A A/G
MAF in parents 0.277 0.443 0.493 0.0769
Minor allele
transmissions
Transmitted 815 1309 915 446
Untransmittedb 790 1386 942 446
Genotype 2/2
Transmitted 1,150 (53.1) 947 (33.3) 798 (33.0) 2,501 (84.8)
Untransmittedb 3,478 (53.6) 2,724 (31.9) 2,352 (32.4 7,489 (84.6)
Genotype 2/1
Transmitted 849 (39.2) 1,382 (48.5) 885 (36.6) 423 (14.3)
Untransmittedb 2,541 (39.1) 4,226 (49.5) 2,685 (37.0) 1,297 (14.7)
Genotype 1/1
Transmitted 166 (7.7) 519 (18.2) 737 (30.5) 27 (0.91)
Untransmittedb 476 (7.3) 1,594 (18.7) 2,223 (30.6) 67 (0.8)
OR for minor allele
(95% CI)
1.03 (0.93–1.14) 0.94 (0.87–1.01) 0.97 (0.89–1.06) 1.00 (0.88–1.14)
a Deletion/insertion polymorphism
bUntransmitted (pseudocontrol) genotypes are estimated as previously described [8]
Multilocus test p=0.425
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associated at age 7 to 8 years (R2=0.030; p=0.055; ESM
Table 4). Results of IGF-1 protein level associations with
individual SNPs are shown in Table 2. However, the
multilocus IGF1 tag-SNP set did not associate with any
other childhood growth or metabolic phenotype (ESM
Table 4). No associations were observed between the
IGF1 CA repeat and IGF-1 concentrations or any growth
or metabolic phenotype (ESM Table 5).
Discussion
We used a UK birth cohort, ALSPAC, and a large
family collection of type 1 diabetes to explore associ-
ation with a subset of SNPs generated by in-depth
resequencing of the IGF1 locus. A subset of SNPs that
effectively predicted the genotype of the remainder was
subsequently genotyped in these cohorts [9]. We report no
evidence to support the hypothesis that genetic variation in
IGF1 is associated with major susceptibility to type 1
diabetes. However, genetic variation in this locus may
modestly influence circulating IGF-1 concentrations, at
least at birth and during childhood.
Prior studies examining the role of genetic variation in
IGF1 in predisposition to common human disease have
focused on a microsatellite in the region 5′ to IGF1. This
variant has been inconsistently associated with adult height
and type 2 diabetes [6, 7]. Perplexingly, the same allele has
been associated with high [6] and low [7] IGF-1 concen-
trations. It is possible that other common genetic variants,
in different degrees of linkage disequilibrium with this
variant, alter IGF-1 concentrations and explain the discrep-
ancy in the published studies.
We found no association between this microsatellite and
circulating IGF-1 concentrations, growth or type 1 diabetes.
To exclude the possibility that other polymorphisms in the
gene predispose to disease, we undertook a systematic
analysis of IGF1 gene variation using tagging SNPs [8].
Our relatively large white type 1 diabetes family collection
of European ancestry provided ~84% power to detect a
causal allele for type 1 diabetes predisposition with MAF=
0.1 and OR of 1.2 at the 5% significance level. The study
was therefore adequately powered to detect weak predis-
position to type 1 diabetes conferred by IGF1. We did not
directly examine whether these variants alter the age at
diagnosis of type 1 diabetes, since there was no primary
evidence of association.
The possibility remains that variation in IGF1 could alter
insulin secretion or action as well as childhood growth.
Therefore, to examine these associations, we adopted the
same strategy in an established birth cohort. While we
demonstrate that common genetic variation in IGF1
modestly influences circulating IGF-1 concentrations at
birth and during childhood, we did not find a major
contribution of IGF1 to birthweight, growth or response
to oral glucose. It remains possible that maternal IGF1
genotypes that influence maternal metabolism might alter
birth size, but they are unlikely to significantly impact on
childhood growth.
In summary, this large systematic study shows that
common IGF1 variants modestly influence circulating IGF-
1 concentrations at birth and during childhood. However,
these variants are not associated with birthweight, child-
hood growth and insulin secretion or action. Moreover they
do not alter type 1 diabetes risk.
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(3.9)
157.4 (9.1) 0.581
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genotype
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